Selank vs Semax: Nootropic Peptide Comparison

Overview

Semax and Selank are both synthetic heptapeptides developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Despite their shared origin and structural similarity — both seven amino acids long, both ending in a Pro-Gly-Pro extension — they act on completely different receptor systems and produce divergent research outcomes.

Semax is cognitively activating. Selank is anxiolytic and stabilising. Understanding the mechanistic basis for this difference is essential for selecting the correct compound for a given research protocol.

Both compounds have been studied in Russian preclinical and clinical settings since the 1980s and 1990s. Both are approved drugs in Russia and Ukraine, where they are available as prescription nasal sprays. Outside those markets, they are supplied as research compounds.

Mechanisms of Action

Semax

Semax is a synthetic analogue of the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension that protects it from rapid enzymatic degradation. Its primary research-established mechanism is upregulation of Brain-Derived Neurotrophic Factor (BDNF) and its high-affinity receptor TrkB in the hippocampus, prefrontal cortex, and striatum. BDNF is the key mediator of neuroplasticity, long-term potentiation, and synaptogenesis — the cellular mechanisms underlying learning and memory.

Additional mechanisms identified in research include:

• •Upregulation of NGF (Nerve Growth Factor)
• •Modulation of dopamine and serotonin receptor sensitivity
• •Inhibition of hippocampal enkephalinase activity
• •Neuroprotective effects via reduced glutamate excitotoxicity in ischaemia models

Selank

Selank is a synthetic analogue of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), with the same C-terminal Pro-Gly-Pro extension used in Semax. Its primary mechanism involves modulation of the GABA-A receptor complex — it potentiates GABAergic inhibitory tone without binding directly to the benzodiazepine site, a distinction with significant implications for its side-effect profile.

Additional mechanisms include:

• •Inhibition of enkephalin-degrading enzymes (prolyl endopeptidase, dipeptidyl peptidase), elevating endogenous anxiolytic peptide concentrations
• •Modulation of serotonin receptors (5-HT1A and 5-HT2A)
• •Upregulation of interleukin-6 and immune system modulation (derived from its tuftsin origin)
• •Weak BDNF upregulation (substantially less than Semax)

Mechanism Comparison Table

Research Findings: Semax

The most replicated preclinical finding for Semax is BDNF upregulation. A study by Dolotov et al. published in the Journal of Neurochemistry demonstrated that a single intranasal dose of Semax produced a 1.4 to 1.7-fold increase in BDNF mRNA in the hippocampus and frontal cortex of rats within 24 hours, with effects persisting for 72 hours despite the compound's short plasma half-life. This demonstrates the critical distinction between plasma half-life and biological effect duration.

Russian clinical research conducted between 1999 and 2011 examined Semax in multiple settings:

• •Ischaemic stroke recovery — significant improvements in neurological deficit scores compared to control groups in multiple trials
• •Optic nerve atrophy — improved visual acuity metrics over 10-day administration courses
• •Cognitive performance under stress — reduced cognitive performance decrements in high-stress operational conditions
• •ADHD-adjacent attentional research — improved sustained attention measures in paediatric subjects

The stimulating quality of Semax is well-documented in animal models: studies consistently show increased locomotor activity, exploratory behaviour, and improved operant learning task performance. Some models show mild anxiety-like behaviour at higher doses, which is one reason Selank is sometimes paired with Semax in combined research protocols.

Research Findings: Selank

The most replicated preclinical finding for Selank is anxiolytic activity without sedation. A seminal study by Semenova et al. demonstrated that Selank produced robust anxiolytic effects in elevated plus-maze and open field tests at doses far below those producing any sedative or motor-impairing effects — a profile clearly distinct from benzodiazepines.

Russian clinical research has examined Selank across several areas:

• •Generalised anxiety disorder — compared favourably against medazepam (a benzodiazepine) with superior cognitive side-effect profile and no sedation
• •Neurasthenia — improved cognitive and emotional functioning over 14-day courses
• •Asthenic syndrome — improved energy, mood, and cognitive performance without stimulant effects or crash
• •Immune function — documented interleukin-6 upregulation consistent with tuftsin's known immunomodulatory properties

Unlike benzodiazepines, no tolerance, dependency, or withdrawal effects were observed in available clinical data. This is mechanistically consistent with Selank's indirect GABAergic action rather than direct benzodiazepine-site agonism.

Direct Comparison: Research Effects Profile

Selecting the Right Compound for a Research Protocol

The selection depends entirely on the research question:

Choose Semax when the protocol investigates: cognitive enhancement, BDNF signalling, neuroprotection, or learning and memory. Semax is appropriate for models examining cognitive activation, neural plasticity, and recovery from neurological insult.

Choose Selank when the protocol investigates: anxiety models, stress resilience, anxiolytic mechanisms without sedation, or GABAergic pharmacology. Selank is appropriate for research into calming, GABA-adjacent mechanisms, and anxiolysis without the dependency liability of benzodiazepines.

Consider both for research examining the interaction between cognitive performance and anxiety — a common confound in nootropic research. Their complementary mechanisms (Semax activating, Selank anxiolytic) make them a logical combination in protocols where balanced cognitive enhancement is the research goal.

Reconstitution and Storage

Both peptides are lyophilised powders supplied in 10mg vials. Add 1-2mL of bacteriostatic water slowly along the inner vial wall. Swirl gently until dissolved. Do not shake. Both solutions should be clear and colourless.

Store lyophilised vials at -20 degrees Celsius for up to 24 months. Store reconstituted solutions at 2-8 degrees Celsius for up to 4 weeks. Protect from light.

Selank 10mg and Semax 10mg are both available individually. The Nootropic Research Bundle includes Semax, Selank, and bacteriostatic water together. Bacteriostatic Water 10mL and 31G insulin needles are required for reconstitution.

Disclaimer: Semax and Selank are research compounds for in-vitro laboratory use only. Not for human consumption, therapeutic, or veterinary use. All information relates to preclinical and clinical research findings published in peer-reviewed literature.